Nivolumab for newly and recurrent glioblastoma multiforme treatment: A systematic review and meta-analysis.

Alexandre Wendell Araújo MouraSirlene da Silva RodriguesTaciana Freire de OliveiraBeatriz Marques LobatoNatalia Neto Pereira CerizePatricia Léo

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

In conclusion, Nivolumab demonstrated promising results that warrant further investigation for its use in newly diagnosed glioblastoma patients. However, its effectiveness was not observed in the context of recurrent GBM.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
randomized controlled trial
chronic kidney disease
systematic review
prognostic factors
peritoneal dialysis
patient reported outcomes
replacement therapy
smoking cessation